IPO
The Annual General Meeting of BioArctic AB on May 9, 2019, adopted instructions regarding the appointment of the Nomination Committee.
Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services.
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, will announce a trading update for the nine-months ended 30 September 2019 on Tuesday, 5 November 2019.
Recipharm, the contract development and manufacturing organisation, and CTC Clinical Trial Consultants have strengthened their partnership with the divestment of Recipharm’s GLP bioanalysis business to the Center for Translational Research AB group.
Amgen announced that it has agreed to acquire a 20.5% stake in BeiGene for approximately $2.7 billion in cash and concurrently has entered into a strategic collaboration pursuant to which BeiGene will commercialize XGEVA®, KYPROLIS® and BLINCYTO® in China and advance 20 medicines from Amgen’s innovative oncology pipeline in China and globally.
Investment in Michigan Facility Targets Future Growth for High-Demand Natural Insecticide Technology
GAAP earnings per share (EPS) from continuing operations was a loss of $(0.69) for the third quarter and operating EPS1 was a loss of $(0.39) – both improved compared to prior year.
Further German cooperation with the Paracelsus Clinic in Zwickau and first NanoTherm treatment center outside of Germany opened at the Independent Public Clinical Hospital No. 4 (SPKS4) in Lublin, Poland
MorphoSys AG reported its financial results for the third quarter of 2019.
Esperion announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open..
PRESS RELEASES